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Abstract: Background: Meniere disease (MD) is an inner ear disorder associated with comorbidities
such as autoimmune diseases or migraine. This study describes clinical and cytokine profiles in
MD according to the age of onset of the condition. Methods: A cross-sectional study including
83 MD patients: 44 with early-onset MD (EOMD, <35 years old), and 39 with late-onset MD (LOMD,
>50 years old), 64 patients with migraine and 55 controls was carried out. Clinical variables and
cytokines levels of CCL3, CCL4, CCL18, CCL22, CXCL,1 and IL-1β were compared among the
different groups. Results: CCL18 levels were higher in patients with migraine or MD than in controls.
Elevated levels of IL-1β were observed in 11.4% EOMD and in 10.3% LOMD patients and these levels
were not dependent on the age of individuals. EOMD had a longer duration of the disease (p = 0.004)
and a higher prevalence of migraine than LOMD (p = 0.045). Conclusions: Patients with EOMD have
a higher prevalence of migraine than LOMD, but migraine is not associated with any cytokine profile
in patients with MD. The levels of CCL18, CCL3, and CXCL4 were different between patients with
MD or migraine and controls.
Keywords: hearing loss; vertigo; migraine; cytokines; inflammation; vestibular disorders
1. Introduction
Patients with acute vertigo and a history of episodic vestibular symptoms represent a
diagnostic challenge for clinicians [1,2]. Particularly, Meniere disease (MD), an inner ear
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disorder characterized by sensorineural hearing loss (SNHL), attacks of episodic vertigo, is
usually associated with tinnitus [3]. Some patients with MD also have migraine headaches
and they usually show an early onset of auditory and vestibular symptoms [4,5].
Although the majority of MD patients are considered sporadic [3], familial clustering
has been reported in 8% and 6% of cases in the Spanish [6] and South Korean populations [7].
Several genes have been identified in familial MD by exome sequencing, the most common
being OTOG, found in 30% of familial cases [8]. Familial cases usually show early age of
onset, but some non-familial cases (sporadic) may also develop the disease in the third
decade of life. The mechanisms leading to this early onset of symptoms are not well
understood and they may involve genetic, epigenetic, and environmental factors.
The epidemiological association of MD with migraine and some autoimmune diseases,
supports the hypothesis of a wide clinical spectrum with a cochleo-vestibular phenotype.
However, the effect of autoimmunity or migraine on the onset of the condition has not
been investigated. Previous studies have shown that MD can be classified according to few
clinical predictors, and it is possible to define subsets within unilateral MD (UMD) and
bilateral MD (BMD) patients (Table 1) [4,5].
Table 1. Clinical subgroups of patients with unilateral and bilateral Meniere disease. Modified from
Frejo et al. [4,5].
Unilateral Ménière’s Disease (UMD)
Type 1: Sporadic and classical MD.
Type 2: Delayed MD
(hearing loss precedes vertigo attacks in months or years).
Type 3: Familial MD
(at least two individuals with MD related in the first or second degree).
Type 4: Sporadic MD with migraine
(temporal relationship not required).
Type 5: Sporadic MD plus an autoimmune disease.
Bilateral Ménière’s Disease (BMD)
Type 1: Unilateral hearing loss becomes bilateral.
Type 2: Sporadic, simultaneous hearing loss (usually symmetric).
Type 3: Familial MD
(most families have bilateral hearing loss, but unilateral and bilateral cases may coexist in the
same family).
Type 4: Sporadic MD with migraine.
Type 5: Sporadic MD with an autoimmune disease.
The age of onset in patients with MD may differ according to the clinical subgroup.
Interestingly, patients with MD and migraine (type 4) and individuals with MD with a co-
morbid autoimmune condition (type 5) have an earlier age of onset than MD type 1 or 2 [5].
Moreover, it was also observed that MD types 4 and 5 have more vertigo attacks than the
other groups [5]. Thereby, individuals with BMD showed an earlier age of onset, associated
with a worse score in the AAO-HNS functional scale than patients with UMD among
familial cases [6].
Previous studies have reported that basal levels of proinflammatory cytokines may
be increased in some patients with MD [9], but the relationship between cytokine levels
with the age of onset, migraine, or autoimmunity has not been investigated. The cytokine
profile may represent two subgroups of MD patients with intrinsic differences in the
immune response or two functional states of the immune system in patients with MD [9,10].
The studies mentioned before had defined different clinical subgroups in patients with
UMD or BMD, but patients with MD and increased basal levels of cytokines and negative
autoantibodies may be considered as an autoinflammatory condition of the inner ear [11].
The aim of the study is to characterize the clinical and cytokine profile, according to
the age of onset in MD.
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2. Experimental Section
2.1. Patient Assessment and Selection
A cross-sectional study was designed to recruit a total of 83 patients with MD. Eighteen
of them were also included in a previous study [10]. Forty-four patients were considered
as early-onset MD (EOMD, age of onset < 35 years old), 39 patients were classified as
late-onset MD (LOMD, age of onset > 50 years old). We also recruited 64 migraine patients
and 55 healthy controls that were selected from the MeDiC database to compare clinical
and cytokine profiles among the different groups. All patients with MD were diagnosed
according to the diagnostic criteria for MD described by the International Committee for
the Classification Vestibular Disorders of the Barany Society [3], and a clinical evaluation
was performed after obtaining informed consent. Patients with migraine were diagnosed
according to the diagnostic criteria for migraine of the International Headache Society [12].
Patients with diagnostic criteria for vestibular migraine [13] were excluded from this study.
The experimental protocol of this study was approved by the Institutional Review
Board in all participating hospitals, and each participant signed a written informed consent
before donating blood samples (PE-0356-2018). The study was carried out according to the
principles of the Declaration of Helsinki revised in 2013 for investigation with humans.
A complete audiological and vestibular assessment was carried out in all MD cases,
including the following variables, sex, age, age of onset, duration of the disease, type of
MD (uni/bilateral), main associated comorbidities (migraine, autoimmune disorders), and
cytokine levels in peripheral venous blood. Serial pure-tone audiograms were retrieved
from clinical records to assess hearing loss since the initial diagnosis. Clinical features of
migraine patients recruited in the study are included in Table S1.
2.2. Peripheral Blood Mononuclear Cell (PBMC) Isolation and Incubation
Peripheral blood was diluted 1:1 with 1× PBS and disposed carefully into the corre-
sponding 20:12 volume of Lymphosep, lymphocyte separation media (Biowest, Nuaillé,
France). Samples were centrifuged for 20 min at 2000 rpm to separate blood content.
PBMCs were collected and washed with 1× PBS twice and cultured in RPMI 1640 sup-
plemented with 10% (v/v) fetal bovine serum (Biowest, Nuaillé, France) and plated at a
concentration of 1 × 106 cells/mL in 6-well plates. PBMCs were incubated overnight at
37 ◦C in 7% CO2. After the incubation, PBMCs were centrifuged, and supernatants were
collected and stored at −80 ◦C until enough samples were acquired.
2.3. Cytokine Measurement
Frozen samples were thawed immediately prior to analysis and none of the samples
underwent more than two freeze–thaw cycles prior to analysis. One cytokine (IL-1β) and
five chemokines (CCL3, CCL4, CXCL1, CCL22, and CCL18) were measured using the
commercially available Multiplex Bead-Based Kits (EMD Millipore, Billerica, MA, USA).
The measurements were performed in accordance with the kit-specific protocols provided
by Millipore, using a Luminex 200 platform (Luminex Corp., Austin, TX, USA) and read
with Luminex x PONENT 3.1 software (Luminex Corp.). Two quality controls for each
cytokine were run in duplicate.
2.4. Statistic and Data Analysis
A descriptive analysis was conducted using GraphPad Prism v8.0 (GraphPad Soft-
ware, San Diego, CA, USA) for the clinical and cytokine data. Quantitative variables
were displayed as the mean and standard deviation (SD). Qualitative variables were
compared using Chi-square and Fisher exact test. Quantitative variables were compared
using U Mann–Whitney test and the Pearson correlation coefficient. Analysis of variance
(ANOVA) was used to compare the three groups of the study (MD, migraine patients, and
healthy controls). The level of significance considered was p < 0.05. To find and remove the
cytokines outlier values, we considered outlier values that were:
J. Clin. Med. 2021, 10, 4052 4 of 14
1.5 × IQR > Q3
1.5 × IQR < Q1,
where Q1 is the median of the lower half of the data set, Q3 is the median of the upper half
of the data set, and IQR is the interquartile range, the difference from Q3 to Q1, [14]. Thus,
from the total cytokines’ measures of 61 MD patients, 64 migraine patients, and 55 control,
we used 56, 59, and 42 measures respectively.
3. Results
3.1. Clinical Profile in Early and Late Onset MD
Table 2 includes all patients with EOMD. Twenty-three patients had been diagnosed
as unilateral MD (54.5%) and 21 were considered bilateral MD (45.5%). Twenty-six (59%)
were women and 18 (41%) were men.
Table 2. Clinical features and basal levels of IL-1β cytokine in patients with EOMD (n = 44). Elevated levels of IL-1β are
highlighted in bold type.
Patient Gender Ear Age ofOnset
Duration of





1 Woman Bilateral 34 8 Yes Yes 3 3.68
2 Woman Bilateral 33 8 Yes Yes 3 1.24
3 Woman Unilateral 28 12 No Yes 4 0.82
4 Man Unilateral 29 9 No No 1 1.57
5 Woman Bilateral 33 24 No Yes 4 3.20
6 Woman Bilateral 18 34 Yes No 3 4.74
7 Woman Unilateral 28 27 No X 4 1.41
8 Woman Unilateral 20 1 Yes Yes 3 18.64
9 Woman Unilateral 28 8 No No 2 3.69
10 Woman Unilateral 29 20 Yes Yes 3 2.79
11 Man Bilateral 27 16 No No 2 2.64
12 Woman Bilateral 33 8 No Yes 4 2.10
13 Woman Bilateral 24 15 No Yes 4 28.45
14 Woman Bilateral 33 17 No No 5 1.66
15 Woman Bilateral 23 18 No Yes 4 1.59
16 Man Bilateral 31 15 No Yes 1 1.25
17 Man Unilateral 34 8 No No 1 0.49
18 Woman Unilateral 27 17 No No 1 2.11
19 Man Bilateral 35 16 No No 1 0.92
20 Woman Bilateral 34 20 No No 1 3.68
21 Woman Unilateral 35 20 Yes No 3 0.01
22 Man Bilateral 29 15 No No 2 0.18
23 Man Unilateral 29 11 No No 1 0
24 Man Unilateral 24 1 No No 1 1.84
25 Man Unilateral 30 27 No Yes 1 46.41
26 Man Bilateral 27 22 No No 1 0
27 Man Unilateral 32 3 No No 1 2.77
28 Man Bilateral 22 23 Yes Yes 1 0.44
29 Woman Bilateral 31 5 No Yes 1 1.14
30 Man Bilateral 22 22 No No 1 1.57
31 Man Bilateral 25 25 No No 1 0.31
32 Man Bilateral 34 34 No No 1 1.14
33 Man Bilateral 28 18 No No 1 18.18
34 Woman Unilateral 28 25 No No 5 2.19
35 Woman Unilateral 23 50 No No 1 3.14
36 Woman Unilateral 29 30 No No 5 6.66
37 Woman Unilateral 23 50 No No 1 3.07
38 Man Unilateral 27 5 No No 1 1.79
39 Woman Unilateral 18 18 Yes Yes 3 4.68
40 Woman Unilateral 35 20 No No 1 0
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Table 2. Cont.
Patient Gender Ear Age ofOnset
Duration of





41 Woman Unilateral 21 2 Yes No 3 0
42 Man Unilateral 24 28 Yes No 3 0.80
43 Woman Unilateral 18 9 Yes Yes 2 0.69
44 Woman Unilateral 24 28 No Yes 4 1.37
Table 3 shows all individuals with LOMD. Twenty-six (67%) had been diagnosed
as unilateral MD and 13 had bilateral MD (33.3%). Twenty-one (54%) were women and
18 (46%) men.
Table 3. Clinical features and basal levels of IL-1β cytokine in patients with LOMD (n = 39). Elevated levels of IL-1β are
highlighted in bold type.
Patient Gender Ear Age ofOnset
Duration of





1 Man Bilateral 55 20 No No 2 0.83
2 Woman Unilateral 65 8 Yes No 3 1.23
3 Man Unilateral 50 13 No No 1 1.56
4 Man Bilateral 55 30 No No 2 2.24
5 Man Unilateral 61 16 No No 1 2.64
6 Woman Unilateral 50 23 Yes No 3 2.10
7 Man Bilateral 53 16 No No 2 3.14
8 Woman Unilateral 50 8 No No 1 2.67
9 Man Bilateral 53 30 No No 2 4.34
10 Man Unilateral 50 14 Yes No 3 6.93
11 Man Unilateral 62 1 No Yes 4 0.01
12 Woman Unilateral 52 17 No Yes 4 0.57
13 Woman Bilateral 56 24 No No 2 2.27
14 Woman Unilateral 55 10 No No 1 2.06
15 Woman Unilateral 63 13 Yes Yes 3 1.07
16 Man Bilateral 56 5 No No 2 0.58
17 Man Unilateral 53 2 Yes Yes 3 0.01
18 Man Bilateral 54 3 No No 2 1.03
19 Woman Bilateral 53 4 No Yes 4 2.67
20 Man Bilateral 55 17 Yes No 3 1.27
21 Woman Unilateral 50 20 Yes No 3 1.73
22 Woman Bilateral 55 9 Yes Yes 3 5.95
23 Woman Unilateral 50 8 No No 1 3.07
24 Woman Bilateral 52 6 No No 2 1.03
25 Man Bilateral 53 2 Yes Yes 3 3.68
26 Woman Unilateral 56 2 No No 1 0.83
27 Man Unilateral 57 2 No No 1 1.66
28 Man Bilateral 53 7 No No 2 0.39
29 Woman Unilateral 65 1 No Yes 4 4.96
30 Man Unilateral 69 2 No No 1 0.76
31 Man Unilateral 66 5 No No 1 2.33
32 Woman Unilateral 51 5 No No 1 4.67
33 Woman Unilateral 63 6 No No 1 3.94
34 Woman Unilateral 61 6 No No 1 1.25
35 Man Unilateral 51 7 No No 1 1.52
36 Woman Unilateral 50 8 No No 1 5.79
37 Woman Unilateral 54 1 Yes No 3 1.32
38 Woman Unilateral 57 6 Yes No 3 1.47
39 Woman Unilateral 54 7 No Yes 1 3.47
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There was no difference in the frequency of FMD between patients with EOMD
(11 patients, 25%) and LOMD (11 patients, 28%). Eighteen years was the mean duration of
the disease in EOMD patients, whereas in LOMD patients the mean was 9.8 years old. In
our series, elevated levels of IL-1β (>4.78 pg/mL) were observed in 5 of 44 (11.3%) patients
with EOMD and in 4 of 39 (10.3%) patients with LOMD.
3.2. EOMD Has a Higher Prevalence of Migraine Than LOMD Patients
Table 4 compares the clinical features of patients with EOMD and LOMD. Patients
with EOMD had a longer duration of the disease, defined as the time since the onset of the
symptoms than patients with LOMD (p = 0.004). As expected, both groups of MD patients
had similar hearing loss thresholds, familial history of hearing loss, and prevalence of
vascular risk factors. However, EOMD patients presented a higher frequency of migraine
than LOMD patients (p = 0.045), but no differences were found for any type of headache
between both groups.
Table 4. Clinical features of patients with EOMD and LOMD included in the study. Migraine was
more frequently observed in patients with EOMD.
Variable EOMD(n = 44)
LOMD
(n = 39) p-Value
Duration of the disease (mean ± SD) 18.0 ± 11.4 9.8 ± 7.9 0.0004
Age of onset (mean ± SD) 27.7 ± 4.9 55.6± 5.2 <0.0001
Sex (% female) 59.0 53.8 0.195
Bilateral hearing loss (%) 45.5 33.3 0.545







Hearing loss (%) 0.357
High frequency 61.4 69.2
Low frequency 38.6 30.8
Family History of hearing loss (%) 25.0 28.2 0.999
Any Headache (%) 59.0 56.4 0.440
Migraine (%) 38.6 23.0 0.045
Arterial Hypertension (%) 22.7 25.6 0.948
Smoking (%) 13.6 10.3 0.532
Dyslipidemia (%) 18.2 28.2 0.400
Diabetes Mellitus (%) 25.0 25.6 0.854
Significant differences (p < 0.05) are highlighted in bold.
3.3. Cytokine Levels Do Not Allow to Distinguish between EOMD and LOMD Patients
Cytokines were measured in 56 MD patients (40 EOMD and 16 LOMD). We did not
observe any differences between the levels of IL-1β or any of the chemokines CCL3, CCL4,
CXCL1, CCL22, CCL8 (all p-values > 0.1, (Figure S1). However, when we performed a
sex-specific analysis, there were significant differences in EOMD for IL-1β, with higher
values in men (p = 0.039), and for CXCL1 with higher values in women (p = 0.007, Figure 1).
Moreover, CCL3 levels were significantly higher in LOMD women than men (p = 0.04).
3.4. Cytokines Levels Do Not Differ between Patients with and without Migraine in MD
Since patients with EOMD presented a higher prevalence of migraine than LOMD
(p = 0.045), we compared cytokines levels considering migraine as a clinical covariable.
However, none of the cytokines or chemokines measured showed significant differences
between patients with and without migraine in MD (Figure 2). Interestingly, the prevalence
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of a comorbid autoimmune disease was significantly higher in patients with MD and
migraine compared to patients without migraine (p < 0.001).
We also separated MD patients according to IL-1β levels into two groups: MD with
high levels of IL-1β (MDH) and low levels of IL-1β (MDL) (Figure 3). However, we found
no difference in the relative frequency of patients according to the clinical subgroups and
IL-1β levels (Table 5).
Table 5. Frequency distribution of patients with MD according to the clinical subgroup and IL-
1β levels.
Variable MDH(n = 9)
MDL
(n = 74) p-Value
MD type (%) 0.9924
1 3 (33.3) 33 (44)
2 0 (0) 13 (14.6)
3 3 (33.3) 17 (22.9)
4 2 (22.2) 9 (12.1)
5 1 (11.1) 2 (2.7)
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3.5. Cytokines Levels Do Not Differ between Familial (FMD) and Sporadic (SMD) MD Patients
We observed that the IL-1β levels were not different between familial and sporadic MD,
however, significant differences were found in CXCL1 (p = 0.024) and CCL22 (p = 0.012),
(Figure 4). Moreover, CXCL1 and CCL22 levels showed a higher correlation in FMD
(r = 0.62) than in sporadic cases (r = 0.37).
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Levels of IL-1β, CCL3, CCL4, CXCL1, CCL22, and CCL8 were also measured in
55 healthy controls and 64 migraine patients. Significant differ nces were fo nd in the
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We could observe that the levels of CCL18 were higher in patients with MD or migraine
when they were compared to controls. However, CCL18 levels did not allow to distinguish
between MD and migraine (p = 0.74). Moreover, no correlation was found in CCL18 levels
and the age of the patients, either in controls (p = 0.59), patients with MD (p = 0.43), or
migraine (p = 0.23) (Figure S2).
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This study a l clinical profile and the l v ls of several cytokines and chemokines
(IL-1β, CCL3, CL4, CL22, CCL18, and CXCL1) in patients with MD, according to the
age of onset f the disease. The age of onset in MD follows a normal distribution [4,5] with
a mean of ~43 years old. We se ected Spanish MD patients < 35 a d >50 years from the
Meniere Diseas Consortium to investigate clin c l features in pati nts with arly- and
late onset, respectively. The time of onset was confirmed from the medical records
The main finding is that migraine is more frequently observed in patients with EOMD
than in LOMD, but the levels of cytokines are not related o the age of onset in MD.
Previous studies have reported that ~20% of patients with MD show hi h levels of pro-
inflammatory cytokines, including IL-1β, TNF-α, and IL-6 [9]. Moreover, Flook et al. (2019)
revealed significant differences in several cytokines and chemokines between patients
with MD and vestibular migraine, suggesting that this set of protein biomarkers could
distinguish MD and vestibular migraine [10].
The findings in this study do not support the hypothesis that the peripheral profile
of immune molecules is related to the age of onset in MD or the presence of migraine.
Therefore, we measured the levels of IL-1β, CCL3, CCL4, CXCL1, CCL22, and CCL18 in a
cohort of 83 patients with MD, which included 44 EOMD and 39 LOMD, and 64 patients
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with migraine without vestibular symptoms to control the effect of migraine itself on
cytokine levels.
We tested the hypothesis that activation of IL-1β signaling contributes to maintaining
an autoinflammatory response in MD, however, this response is not age-dependent. Con-
sidering that we observed a cytokine increase in PBMCs extracted from peripheral blood,
this could indicate that a subgroup of patients with MD has a systemic pro-inflammatory
response, which could explain some patient’s responses to anti-inflammatory drugs [15,16].
Our study shows that IL-1β concentrations are not age-dependent, neither in MD patients
nor healthy controls. Of note, we also found that IL-1β levels are higher in a subgroup of
patients with migraine, suggesting a pro-inflammatory state in these patients.
We observed that EOMD patients have a higher prevalence of migraine as a comorbid
condition compared to LOMD. This finding confirms the observation reported by Frejo
et al. that patients with MD and migraine (type 4) presented an earlier onset than the rest
of patients with MD [4,5].
In addition, the clinical association between autoimmunity and MD suggests the
possibility of an autoimmune endophenotype according to the immune role of the en-
dolymphatic sac or the synthesis of cytokines [17]. There are two different endotypes of
MD patients, according to the pathology of the endolymphatic sac: one endotype charac-
terized by the epithelial degeneration of the endolymphatic sac and a second endotype
showing hypoplasia of the endolymphatic sac [18]; however, the cytokine profile or the
association with migraine with the hypoplastic or degenerative endolymphatic sac has not
been investigated.
To our knowledge, this is the first study in which inflammatory biomarkers and
clinical phenotypes were simultaneously assessed both in adult men and women with
early-onset as well as late-onset MD. We found an overall reduction in the systemic levels
of inflammatory markers in men with EOMD or LOMD, where significant differences were
observed for IL-1β, CXCL1, and CCL3. Moreover, we observed no significant differences
in other inflammatory biomarkers between groups.
Familial MD has an earlier onset than sporadic cases, suggesting that early-onset
patients might have a higher genetic burden, including patients with a potential recessive
inheritance. Previous studies have shown that there is an enrichment of rare missense
variants in some genes related to hearing loss, such as: GJB2, USH1G, SLC26A, USH1G,
ESRRB, and CLDN14, as well as in some genes implicated in the “axonal guidance signal-
ing” signaling pathway such as NTN4 and NOX3, in patients with sporadic MD [19]. This
excess of missense variants in some genes may increase the risk of developing hearing loss
in MD [20]. We have found higher levels of CXCL1 and CCL22 in familial MD, but the rele-
vance of this finding is unclear. The chemokine CXCL1 recruits and activates neutrophils
to the site of infection [21], and it is essential for the expression of pro-inflammatory media-
tors, activation of NF-kB, and MAPKs [22]. CCL22 is a macrophage-derived chemokine
and a potent chemoattractant for chronically activated T-lymphocytes [23,24]. CCL22 is
thought to be involved in several conditions, including allergy, autoimmunity, and tumor
growth [24], and increased CCL22 expression has been reported in autoinflammatory skin
diseases [25].
There are several mechanisms that may drive the onset of MD. A persistent inflam-
matory response may affect one or both ears and local factors could be involved. The
accumulation of endolymph is the result of inner ear damage usually associated with
sensorineural hearing loss [26].
The autoinflammatory disease of the inner ear might include an innate immune
response mediated by monocytes, IL-1β, and non-specific autoantibodies [27]. In healthy
individuals, IL-1 RA is detectable in plasma and IL-1β levels are usually not detectable.
IL-1 RA levels were more elevated in most patients with MD regardless of the levels of
IL-1β [9]. It was also observed that only 58 genes were differentially expressed in MD
patients with high basal levels of IL-1β, supporting the hypothesis that this abnormal
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response may facilitate the identification of a subgroup of MD patients with a specific gene
expression profile [9].
Cytokines are considered as pain mediators in neurovascular inflammation, and
therefore, they may cause the generation of migraine pain [28]. Changes in inflammatory
activity in migraine patients may be one of the main causes of endothelial dysfunction. The
increase in endothelial cell permeability leads to an increase in the paracellular leakage of
plasma fluid and proteins [29].
Different findings have been reported in the clinical studies measuring cytokine
levels in migraine patients [30–33]. These studies have indicated that immunological
changes could play a role in the pathophysiology of migraine. We can speculate that
increased release of CCL18 observed in patients with migraine in combination with other
pro-inflammatory mediators is likely to contribute to a persistent inflammatory state that
may trigger the onset of MD in susceptible individuals. This subgroup of patients with
MD and migraine may have an earlier onset and higher risk of autoinflammation.
In addition, the lack of correlation between age and IL-1β plasma levels, regardless of
the important role of aging in the immune response, suggests that genetic or epigenetic
factors are needed to develop MD in patients with migraine [34].
Our study shows that a better understanding of how the immune mediators could
influence the age of onset in MD disease is of great relevance to provide clues on potential
strategies to delay the onset of MD in susceptible individuals in an increasingly aged
population.
5. Limitations of the Study
The main limitation of our study is that the number of investigated patients was
low (n = 83), and further patients will be needed to validate our findings. Our study is
limited by the cross-sectional design and the small number of cytokines and clinical data
collected, so it may be not enough to classify patients with MD according to the age of onset.
Moreover, the lack of correlation between the age of individuals and IL-1β or CCL18 levels
suggest inter-individual differences associated with multiple factors, including migraine.
6. Conclusions
1. Patients with EOMD have a higher prevalence of migraine than patients with LOMD.
2. The levels of IL-1β or chemokines were not dependent on the age of the individuals
or the presence of migraine in patients with MD.
3. The levels of CCL18, CCL22, and CCL4 were different between patients with MD or
migraine and controls.
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Figure S2. Scattered plot showing CCL18 levels as a function of age of patients and years of disease
evolution in healthy controls. patients with MD and migraine.
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